Get the Stockscreener App
3.08
2.22%
-0.07
Pre-market:
3.11
0.03
+0.97%
Puma Biotechnology Inc stock is traded at $3.08, with a volume of 1.13M.
It is down -2.22% in the last 24 hours and down -4.64% over the past month.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
See More
Previous Close:
$3.15
Open:
$3.12
24h Volume:
1.13M
Relative Volume:
2.66
Market Cap:
$151.19M
Revenue:
$226.63M
Net Income/Loss:
$15.38M
P/E Ratio:
-61.60
EPS:
-0.05
Net Cash Flow:
$35.61M
1W Performance:
+12.00%
1M Performance:
-4.64%
6M Performance:
-4.64%
1Y Performance:
-29.03%
1-Day Range:
$3.05
$3.38
1-Week Range:
$2.73
$3.38
52-Week Range:
$2.225
$7.73
Puma Biotechnology Inc Stock (PBYI) Company Profile
Name
Puma Biotechnology Inc
Sector
Industry
Phone
(424) 248-6500
Address
10880 WILSHIRE BLVD., LOS ANGELES, CA
Compare PBYI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PBYI
Puma Biotechnology Inc
|
3.08 | 151.19M | 226.63M | 15.38M | 35.61M | 0.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.76 | 105.27B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
712.40 | 78.29B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
626.31 | 37.79B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
237.97 | 30.69B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.95 | 27.28B | 3.30B | -501.07M | 1.03B | -2.1146 |
Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-28-21 | Upgrade | Citigroup | Neutral → Buy |
| Jun-25-20 | Resumed | BofA/Merrill | Underperform |
| Oct-08-19 | Downgrade | Goldman | Neutral → Sell |
| May-10-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| May-10-19 | Downgrade | Citigroup | Buy → Neutral |
| Jan-17-19 | Initiated | Leerink Partners | Mkt Perform |
| Jan-03-19 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-19-18 | Upgrade | Goldman | Sell → Neutral |
| Nov-02-18 | Downgrade | BofA/Merrill | Buy → Underperform |
| Nov-02-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-17-18 | Initiated | Goldman | Sell |
| May-11-18 | Reiterated | Stifel | Buy |
| Nov-10-17 | Reiterated | Citigroup | Buy |
| Nov-10-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Oct-02-17 | Reiterated | Stifel | Buy |
| Sep-11-17 | Reiterated | Credit Suisse | Outperform |
| Jul-10-17 | Resumed | Leerink Partners | Outperform |
| Jun-06-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-25-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Mar-02-17 | Reiterated | RBC Capital Mkts | Sector Perform |
View All
Puma Biotechnology Inc Stock (PBYI) Latest News
Puma biotechnology sales earnings call - Ciudad Florida
Research Analysts Set Expectations for PBYI FY2025 Earnings - Defense World
What Every Investor Should Know: Understanding ROE Can Change Your Game! - Clinique Bio
Puma Biotechnology Stock Rises 24% in 3 Months: Here's Why - Yahoo Finance
Best Value Stocks to Buy for December 24th - MSN
Should You Be Excited About Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 33% Return On Equity? - Simply Wall St
Puma Biotech shares hold as analyst backs Buy rating on NCCN nod - Investing.com Canada
Puma Biotechnology (NASDAQ:PBYI) Given “Buy” Rating at HC Wainwright - Defense World
Best Momentum Stocks To Buy For December 24th - Barchart
Best Momentum Stocks to Buy for December 24th - Yahoo Finance
With 49% stake, Puma Biotechnology, Inc. (NASDAQ:PBYI) seems to have captured institutional investors' interest - Yahoo Finance
HC Wainwright Reiterates Buy Rating for Puma Biotechnology (NASDAQ:PBYI) - MarketBeat
Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer with a HER2 Mutation - Business Wire
XTX Topco Ltd Sells 22,227 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) - Defense World
Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Acquired by Fmr LLC - Defense World
Puma Biotechnology: The Best Performing Biotechs of 2013 - AOL
Charles Schwab Investment Management Inc. Sells 8,574 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) - Defense World
Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Bought by BNP Paribas Financial Markets - Defense World
Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock? - Yahoo Finance
Puma Biotechnology: Continuing To Push Their Aurora Kinase Story Forward - Seeking Alpha
Puma Biotechnology (NASDAQ:PBYI) Lowered to Buy Rating by StockNews.com - MarketBeat
HRMY: 3 Emerging Biotech Stocks Developing Breakthrough Therapies - StockNews.com
PBYIPUMA BIOTECHNOLOGY INC Latest Stock News & Market Updates - StockTitan
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Bakersfield Californian
Should Value Investors Buy Puma Biotechnology (PBYI) Stock? - Yahoo Finance
Discovering Promising US Penny Stocks In November 2024 - Simply Wall St
Puma Biotechnology (NASDAQ:PBYI) Downgraded by StockNews.com to Buy - MarketBeat
PBYI Begins Phase II Study on Alisertib Combo in Breast Cancer - MSN
Puma commences Phase II trial of alisertib for breast cancer treatment - Clinical Trials Arena
Puma Biotech Launches Phase 2 Trial for Advanced Breast Cancer Treatment | PBYI Stock News - StockTitan
Puma Biotechnology Announces Initiation of ALISCA -Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer - Business Wire
245,695 Shares in Puma Biotechnology, Inc. (NASDAQ:PBYI) Bought by Los Angeles Capital Management LLC - MarketBeat
Puma Biotechnology's (NASDAQ:PBYI) Performance Is Even Better Than Its Earnings Suggest - Simply Wall St
We Think Puma Biotechnology's (NASDAQ:PBYI) Robust Earnings Are Conservative - Yahoo Finance
Puma Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Puma Biotechnology Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Puma Biotechnology reports robust Q3 growth - Investing.com
Earnings call: Puma Biotechnology reports robust Q3 growth By Investing.com - Investing.com UK
Puma Biotechnology's (PBYI) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
PBYI Beats Q3 Earnings & Revenue Estimates, Revises '24 View, Stock Up - Nasdaq
Puma Biotechnology Reports Strong Q3 2024 Growth - TipRanks
Puma Biotechnology Q3 2024 Earnings Preview - MSN
Puma Biotech (PBYI) Q3 Earnings and Revenues Surpass Estimates - Yahoo Finance
Puma Biotechnology Reports Third Quarter 2024 Financial Results - sharewise
Puma Biotech: Q3 Earnings Snapshot - San Francisco Chronicle
Puma Biotechnology (NASDAQ:PBYI) Raised to "Strong-Buy" at StockNews.com - MarketBeat
Puma Biotechnology (PBYI) Set to Announce Quarterly Earnings on Thursday - MarketBeat
Puma Biotechnology Inc Stock (PBYI) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.14%
5.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):